Indiana
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in Indiana: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
Indiana has historically followed federal patent law closely, particularly regarding the patent eligibility of biotechnological inventions. The principles articulated in the Myriad case, especially concerning the nature of isolated genes and their patentability, guide Indiana courts in addressing similar patent disputes.
In Indiana, the principle that naturally occurring genes cannot be patented unless they are significantly altered to exhibit new characteristics is upheld, reflecting the federal standard set by the Myriad case.
The court reinforced the application of the Myriad decision by ruling that isolated DNA sequences were not patentable as they are naturally occurring.
The court upheld the decision that patents on biotechnological inventions must meet the requirements of non-obviousness and utility, aligning with the Myriad ruling.
This case highlighted the necessity for significant human intervention to patent biogenetic materials, echoing the Myriad decision's focus on isolation selectivity.
Indiana's application of the principles from Myriad is largely consistent with the federal standard. Both the state and federal courts emphasize that naturally occurring sequences cannot be claimed as inventions without substantial modification.
Understanding Indiana's approach to gene patenting as influenced by Myriad is crucial for the bar exam, especially in questions related to patent eligibility under U.S. and state law.